Fosun gets Chinese rights to Bial's PD drug

Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) granted the Jiangsu Wanbang Biopharmaceutical Group Co. Ltd. subsidiary of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive, Chinese commercialization rights to Parkinson's disease drug Ongentys opicapone. Bial-Portela will receive €2.5 million ($3 million) up front and is eligible for up to €12.5 million ($15 million) in milestones...